DOCSLIB.ORG

Maintenance of Efficacy and Safety of Rabeprazole in Children with Endoscopically Proven GERD

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Maintenance of Efficacy and Safety of Rabeprazole in Children with Endoscopically Proven GERD ORIGINAL ARTICLE:GASTROENTEROLOGY Maintenance of Efficacy and Safety of Rabeprazole in Children With Endoscopically Proven GERD ÃIbrahim Haddad, yJaroslaw Kierkus, zEduardo Tron, §April Ulmer, jjPeter Hu, jjSteven Silber, jjSheldon Sloan, and jjGerhard J. Leitz ABSTRACT Objective: The aim of the present study was to evaluate 24-week main- abeprazole sodium is a substituted benzimidazole molecule þ þ tenance of efficacy and safety of rabeprazole in children with endoscopically R that inhibits H /K ATPase, the proton pump responsible for proven gastroesophageal reflux disease (GERD). the terminal step in gastric acid secretion (1) and is presently Methods: Children ages 1 to 11 years who achieved endoscopic/histologic marketed globally as enteric coated 10- and 20-mg rabeprazole healing (defined as grade 0 of the Hetzel-Dent Classification scale and/or sodium tablets for acute as well as maintenance treatment of adults grade 0 of the Histological Features of Reflux Esophagitis scale) in a with erosive and nonerosive gastroesophageal reflux disease 12-week treatment phase were continued on the same dose for an (GERD), healing of duodenal ulcers, and eradication of Helico- additional 24 weeks during the maintenance phase. The dose was bacter pylori and Zollinger-Ellison syndrome (2,3). Rabeprazole determined by weight: children weighing 6 to 14.9 kg (low-weight is approved in the United States for the short-term treatment of acid- cohort) received 5 or 10 mg and children weighing 15 kg (high-weight related disorders, including GERD, in adolescents. It has been cohort) received 10 or 20 mg. shown to be effective in double-blind, placebo-controlled trials Results: Healing was maintained in 90% of children (100% [low-weight in adults with acid-related GERD, H pylori infection, and peptic cohort]; 89% [10 mg, high-weight cohort]; 85% [20 mg, high-weight ulcer disease (2). It also has been shown to be effective in cohort]). The Total GERD Symptom and Severity score continued to adolescents (12–16 years of age) with GERD. The efficacy charac- improve slightly in all of the children across all dose groups (P ¼ 0.026) teristics and adverse event (AE) profile in adolescents were found during the maintenance phase, except the 10-mg dose group (low-weight to be similar to those reported for adults. There are no data, cohort), which experienced a slight worsening of 3.6 points. Overall, 71% however, from prospectively designed trials in children with GERD children felt better on the GERD Symptom Relief score (P < 0.001); 95% of <12 years. investigators and 92% of parent/caregivers rated ‘‘Good to Excellent’’ on The present study explored the number and percentage of the Global Treatment Satisfaction scale and Clinical Global Impressions children (1–11 years) who had achieved endoscopic/histologic Improvement scale, respectively. Overall incidence of treatment-emergent healing during a preceding 12-week treatment phase and main- adverse events was 63%; upper respiratory tract infections (13%) and tained healing during this 24-week maintenance phase. The safety vomiting (11%) were the most commonly reported (>10%). and efficacy results of the 12-week treatment study are under Conclusions: Rabeprazole was effective in maintaining endoscopic/ publication (4). histologic healing during a 24-week maintenance period in children with endoscopically proven GERD. The clinical effect and safety profile were largely similar across dose groups. METHODS Key Words: endoscopic, gastroesophageal reflux disease, pediatric, Study Design rabeprazole Children 1 to 11 years of age who achieved healing (grade 0 on the Hetzel-Dent Classification and/or grade 0 on the Histological (JPGN 2014;58: 510–517) Features of Reflux Esophagitis scale) by the end of a 12-week, double-blind, treatment phase were offered to continue double- blind treatment at the same dose regimen for an additional 24 weeks, Received January 15, 2013; accepted October 22, 2013. Ã which was either rabeprazole sodium 0.5 or 1.0 mg/kg. The dose From Pediatric & Adolescent Gastroenterology & Nutrition, Youngstown, was further determined by weight: children weighing 6 to 14.9 kg OH, yChildren’s Memorial Health Institute, Warsaw, Poland, zGeisinger Medical Center Clinic, Wilkes-Barre, PA, §Gastrointestinal Associates, (low-weight cohort) received 5 or 10 mg and children weighing Jackson, MS, and jjJanssen Research & Development, LLC, Raritan, NJ. 15 kg (high-weight cohort) received 10 or 20 mg. Address correspondence and reprint requests to Ibrahim Haddad, MD, Before entering the 12-week treatment phase of the study, all Pediatric & Adolescent Gastroenterology & Nutrition, 8560 South of the children were screened for diagnosis of GERD through Avenue, #3, Youngstown, OH 44514 (e-mail: [email protected]). medical history, evaluation of symptoms, and confirmation by www.clinicaltrials.gov registration number: NCT00787891. endoscopy/histology (biopsy). A physical examination was con- The present study is supported by funding from Janssen Research & ducted, medical records were reviewed, and relevant medical Development, LLC (previously known as Johnson & Johnson Pharma- history/current medical conditions were recorded on the appropriate ceutical Research & Development, LLC) and Eisai Medical Research study record form. Children of both sexes, ages 1 to 11 years, were Inc. The sponsors also provided a formal review of this article. G.L., P.H., S.S., and S.S. are employees of Janssen Research & Develop- required to have endoscopically proven GERD (defined as grade ment, LLC. The other authors report no conflicts of interest. 1 on the Hetzel-Dent Classification scale and grade >0 on the Copyright # 2014 by European Society for Pediatric Gastroenterology, Histological Features of Reflux Esophagitis scale) and a history of Hepatology, and Nutrition and North American Society for Pediatric at least 1 GERD symptom (heartburn, dysphagia, belching/burping, Gastroenterology, Hepatology, and Nutrition regurgitation, vomiting, hoarseness, coughing, choking, fullness DOI: 10.1097/MPG.0000000000000229 during eating, anorexia, nausea, abdominal pain) occurring at least 510 JPGN Volume 58, Number 4, April 2014 Copyright 2014 by ESPGHAN and NASPGHAN. Unauthorized reproduction of this article is prohibited. JPGN Volume 58, Number 4, April 2014 Efficacy and Safety of Rabeprazole in Pediatric Patients With GERD 1 to 2 times daily within 3 months before screening. On average, Efficacy and Safety Assessments children had 4 to 5 GERD symptoms at entry. The most prevalent symptom was belching (69%) followed by abdominal pain (68%), The primary efficacy endpoint assessed the number and coughing (62%), fullness while eating (56%), regurgitation percentage of children who had achieved endoscopic/histologic (55%), nausea (42%), heartburn (41%), hoarseness (31%), vomiting healing by the end of the 12-week treatment period and main- (29%), anorexia (27%), dysphagia (23%), and choking (16%). The tained healing during this 24-week maintenance phase. Healing study excluded children with a history of endoscopic findings of was defined as grade 0 on the Hetzel-Dent Classification scale (6), eosinophilic esophagitis, persistent milk protein allergy, allergic and/or grade 0 on the Histological Features of Reflux Esophagitis gastroenteropathy, tracheoesophageal fistula status postrepair, scale (7). Secondary efficacy endpoints included change from the mental retardation, cerebral palsy, and infection with H pylori. end of the treatment phase (week 12) to the end of maintenance The use of sucralfate, domperidone, or any medication that affects phase (week 36) in Total GERD Symptom and Severity, GERD gastrointestinal (GI) motility (caffeine, baclofen, erythromycin, and Symptom Relief, Global Treatment Satisfaction, and CGI-I metoclopramide) as well as digoxin, digitalis preparations, keto- scores. conazole, and theophylline were prohibited from 3 days before The Total GERD Symptom and Severity score assessed randomization in the 12-week treatment phase and throughout the severity and frequency of 12 predefined GERD symptoms, the 24-week maintenance phase. To enter the 24-week maintenance including heartburn, dysphagia, belching/burping, regurgitation, phase of the study, children were required to have achieved healing vomiting, hoarseness, coughing, choking, fullness during eating, (grade 0 on the Hetzel-Dent Classification and/or grade 0 on the anorexia, nausea, and abdominal pain. For each symptom, the Histological Features of Reflux Esophagitis scale) by the end of the frequency (0 ¼ never; 1 ¼ 1–2 times; 2 ¼ 3–4 times; 3 ¼ 5–6 times; preceding 12-week treatment phase. 4 ¼ 7 or more times) and severity (1 ¼ mild; 2 ¼ moderate; The efficacy parameters evaluated at the end of the 12-week 3 ¼ severe) were determined. For each individual symptom, the treatment phase (baseline for the maintenance phase) and at the end score is defined as the sum of the frequency and severity of that of the 24-week maintenance phase (week 36) included esophago- symptom (maximum attainable individual score ¼ 7). The total gastroduodenoscopy (EGD) with histology, Total GERD Symptom score is defined as the sum of the scores of all of the symptoms and Severity score, GERD Symptom Relief score, Global Treatment (maximum attainable total score ¼ 84) (8). Higher observed scores Satisfaction score, and parent/caregiver-rated Clinical Global indicate more serious conditions (8). Impressions Improvement (CGI-I) score. The child’s Overall GERD Symptom Relief was graded as The
Load more

Recommended publications
  • Receptor Antagonist (H RA) Shortages | May 25, 2020 2 2 2 GERD4,5 • Take This Opportunity to Determine If Continued Treatment Is Necessary
    H2-receptor antagonist (H2RA) Shortages Background . 2 H2RA Alternatives . 2 Therapeutic Alternatives . 2 Adults . 2 GERD . 3 PUD . 3 Pediatrics . 3 GERD . 3 PUD . 4 Tables Table 1: Health Canada–Approved Indications of H2RAs . 2 Table 2: Oral Adult Doses of H2RAs and PPIs for GERD . 4 Table 3: Oral Adult Doses of H2RAs and PPIs for PUD . 5 Table 4: Oral Pediatric Doses of H2RAs and PPIs for GERD . 6 Table 5: Oral Pediatric Doses of H2RAs and PPIs for PUD . 7 References . 8 H2-receptor antagonist (H2RA) Shortages | May 25, 2020 1 H2-receptor antagonist (H2RA) Shortages BACKGROUND Health Canada recalls1 and manufacturer supply disruptions may be causing shortages of commonly used acid-reducing medications called histamine H2-receptor antagonists (H2RAs) . H2RAs include cimetidine, famotidine, nizatidine and ranitidine . 2 There are several Health Canada–approved indications of H2RAs (see Table 1); this document addresses the most common: gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD) . 2 TABLE 1: HEALTH CANADA–APPROVED INDICATIONS OF H2RAs H -Receptor Antagonists (H RAs) Health Canada–Approved Indications 2 2 Cimetidine Famotidine Nizatidine Ranitidine Duodenal ulcer, treatment ü ü ü ü Duodenal ulcer, prophylaxis — ü ü ü Benign gastric ulcer, treatment ü ü ü ü Gastric ulcer, prophylaxis — — — ü GERD, treatment ü ü ü ü GERD, maintenance of remission — ü — — Gastric hypersecretion,* treatment ü ü — ü Self-medication of acid indigestion, treatment and prophylaxis — ü† — ü† Acid aspiration syndrome, prophylaxis — — — ü Hemorrhage from stress ulceration or recurrent bleeding, — — — ü prophylaxis ü = Health Canada–approved indication; GERD = gastroesophageal reflux disease *For example, Zollinger-Ellison syndrome .
    [Show full text]
  • Proton Pump Inhibitors
    MEDICATION POLICY: Proton Pump Inhibitors Generic Name: Proton Pump Inhibitors Preferred: Esomeprazole (generic), Lansoprazole (generic), Omeprazole (generic), Therapeutic Class or Brand Name: Proton Pantoprazole (generic), and Rabeprazole Pump Inhibitors (generic) Applicable Drugs (if Therapeutic Class): Non-preferred: Aciphex® (rabeprazole), Esomeprazole (generic), Lansoprazole Dexilant® (dexlansoprazole), Nexium® (generic), Omeprazole (generic), Pantoprazole (esomeprazole), Not Medically Necessary: (generic), and Rabeprazole (generic). Omeprazole/Sodium Bicarbonate (generic), Aciphex® (rabeprazole), Dexilant® Zegerid® (omeprazole/sodium bicarbonate). (dexlansoprazole), Nexium® (esomeprazole), Prevacid® (lansoprazole), Prilosec® Date of Origin: 2/1/2013 (omeprazole), and Protonix® (pantoprazole). Date Last Reviewed / Revised: 12/23/2020 Omeprazole/Sodium Bicarbonate (generic), Zegerid® (omeprazole/sodium bicarbonate). Policy also applies to any other Proton Pump Inhibitors not listed. GPI Code: 4927002000, 4927002510, 4927004000, 4927006000, 4927007010, 4927007610, 4999600260 PRIOR AUTHORIZATION CRITERIA (May be considered medically necessary when criteria I and II are met) I. Documented diagnosis of one of the following A through G: A. Gastroesophageal reflux disease (GERD). B. Erosive esophagitis. C. Gastric ulcers. D. Risk reduction of NSAID-associated gastric ulcer. E. Duodenal ulcers. F. Eradication of H. pylori. G. Hypersecretory conditions II. Non-preferred PPIs require documented trials and failures of all generic PPIs. EXCLUSION
    [Show full text]
  • Comparison of the Efficacies of Proton Pump Inhibitors and H2 Receptor Antagonists in On-Demand Treatment of Gastroesophageal Reflux Disease
    8 ORIGINAL ARTICLE COMPARISON OF THE EFFICACIES OF PROTON PUMP INHIBITORS AND H2 RECEPTOR ANTAGONISTS IN ON-DEMAND TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE Nesibe Vardı1, Emine Köroglu2, Sabah Tüzün3, Can Dolapçıoğlu4, Reşat Dabak5 1Kilimli No: 8104005 Dikmeli Family Health Centre, Duzce, Turkey 2Department of Gastroenterology, Kartal Dr.Lütfi Kırdar Training and Research Hospital, Istanbul, Turkey 3Department of Family Medicine, Kartal Dr. Lütfi Kırdar Training and Research Hospital, Istanbul, Turkey Abstract Objective: On-demand treatment protocols in the maintenance treatment of gastroesophageal reflux disease (GERD) are cost-efficient and easy-to-use treatments.This study aimed to compare the efficacies of H2 receptor antagonists (H2RA) and proton pump inhibitors (PPI) in on-demand treatment of GERD. Methods: Patients with persistent GERD symptoms were enrolledbetween January-November 2015 and were ran- domly separated into two equal groups. The patients in the first group were commenced on ranitidine 300 mg as H2RA and the patients in the second group were commenced on pantoprazole 40 mg. A 4-point Likert-type scale generated by the researchers was applied to evaluate the frequencies of reflux symptoms and their impacts on activities of life and business life. Results: Fifty-two patients were included, of whom 26 (50.0%) were in the PPI group and 26 (50.0%) were in the H2RA group. There were no significant differences between the study groups both before and after treatment in terms of the severity of reflux symptoms. There were significant decreases in the H2RA group in terms of the domains of retrosternal burning sensation, regurgitation, nausea and vomiting, and burping (p=0.036, p=0.027, p=0.020, and p=0.038, respectively).
    [Show full text]
  • Aciphex (Rabeprazole Sodium)
    ACIPHEXÔ çç \ a-sc -**feks\ (rabeprazole sodium) Delayed-Release Tablets DESCRIPTION The active ingredient in ACIPHEXÔ Delayed-Release Tablets is rabeprazole sodium, a substituted benzimidazole that inhibits gastric acid secretion. Rabeprazole sodium is known chemically as 2-[[[4-(3-methoxypropoxy)-3-methyl-2- pyridinyl]-methyl] sulfinyl]-1H–benzimidazole sodium salt. It has an empirical formula of C18H20N3NaO3S and a molecular weight of 381.43. Rabeprazole sodium is a white to slightly yellowish-white solid. It is very soluble in water and methanol, freely soluble in ethanol, chloroform and ethyl acetate and insoluble in ether and n-hexane. The stability of rabeprazole sodium is a function of pH; it is rapidly degraded in acid media, and is more stable under alkaline conditions. The structural formula is: Na N O H3C O CH2 O CH3 S CH2 CH2 N CH2 N RABEPRAZOLE SODIUM ACIPHEXÔ is available for oral administration as delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium. Inactive ingredients are mannitol, hydroxypropyl cellulose, magnesium oxide, low-substituted hydroxypropyl cellulose, magnesium stearate, ethylcellulose, hydroxypropyl methylcellulose phthalate, diacetylated monoglycerides, talc, titanium dioxide, carnauba wax, and ferric oxide (yellow) as a coloring agent. NDA 20-973 (AciphexÔ ) 1 Annotated Package Insert March 5, 1999 CLINICAL PHARMACOLOGY Pharmacokinetics and Metabolism ACIPHEXTM delayed-release tablets are enteric-coated to allow rabeprazole sodium, which is acid labile, to pass through TM the stomach relatively intact. After oral administration of 20 mg ACIPHEX , peak plasma concentrations (Cmax) of rabeprazole occur over a range of 2.0 to 5.0 hours (Tmax). The rabeprazole Cmax and AUC are linear over an oral dose range of 10 mg to 40 mg.
    [Show full text]
  • Proton Pump Inhibitors
    Provider update Hot Tip: Proton pump inhibitors Your Amerigroup Community Care patients may experience a pharmacy claim rejection when prescribed nonpreferred products. To avoid additional steps or delays at the pharmacy, consider prescribing preferred products whenever possible. Utilization Management edits may apply to select preferred products. Coverage should be verified by reviewing the Preferred Drug List (PDL) on the Amerigroup provider website. The PDL is subject to change quarterly. Preferred products Nonpreferred products All brand and generic OTC strengths and All brand and generic prescription strengths formulations1 and formulations • OTC Zegerid (omeprazole-bicarbonate) • Zegerid (omeprazole-bicarbonate) OTC omeprazole-bicarbonate (generic OTC • Omeppi (omeprazole-bicarbonate) Zegerid) • Omeprazole-bicarbonate (generic Rx Zegerid) All brand and generic OTC product strengths and All brand and generic prescription product formulations1 See footnote for reference of strengths and formulations unless otherwise available OTC strengths3 noted • OTC esomeprazole DR (generic Nexium) • Aciphex (rabeprazole) • OTC lansoprazole DR (generic Prevacid) • Dexilant (dexlansoprazole) • OTC Nexium 24hr (esomeprazole) • Esomeprazole (generic Nexium) • OTC omeprazole (generic Prilosec) • Lansoprazole (Prevacid) • OTC Prevacid 24hr (lansoprazole) • Nexium (esomeprazole) • OTC Prilosec (omeprazole) • Omeprazole2 (generic Prilosec) • Pantoprazole (generic Protonix) • Prevacid (lansoprazole) • Prilosec (omeprazole) • Protonix (pantoprazole) • Rabeprazole
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • PHRP March 2015
    March 2015; Vol. 25(2):e2521518 doi: http://dx.doi.org/10.17061/phrp2521518 www.phrp.com.au Research Manual versus automated coding of free-text self-reported medication data in the 45 and Up Study: a validation study Danijela Gnjidica,b,i, Sallie-Anne Pearsona,c, Sarah N Hilmerb,d, Jim Basilakise, Andrea L Schaffera, Fiona M Blythb,f,g and Emily Banksg,h, on behalf of the High Risk Prescribing Investigators a Faculty of Pharmacy, University of Sydney, NSW, Australia b Sydney Medical School, University of Sydney, NSW, Australia c Sydney School of Public Health, University of Sydney, NSW, Australia d Royal North Shore Hospital and Kolling Institute of Medical Research, Sydney, NSW, Australia e School of Computing, Engineering and Mathematics, University of Western Sydney, NSW, Australia f Centre for Education and Research on Ageing (CERA), Concord Hospital, Sydney, NSW, Australia g The Sax Institute, Sydney, NSW, Australia h National Centre for Epidemiology and Population Health, Australian National University, Canberra, ACT i Corresponding author: [email protected] Article history Abstract Publication date: March 2015 Background: Increasingly, automated methods are being used to code free- Citation: Gnjidic D, Pearson S, Hilmer S, text medication data, but evidence on the validity of these methods is limited. Basilakis J, Schaffer AL, Blyth FM, Banks E. To examine the accuracy of automated coding of previously keyed Manual versus automated coding of free-text Aim: in free-text medication data compared with manual coding of original self-reported medication data in the 45 and Up Study: a validation study. Public Health handwritten free-text responses (the ‘gold standard’).
    [Show full text]
  • Acid-Reducing Medications: Interactions with Harvoni and Epclusa
    November 2016 | www.hepatitis.va.gov Acid-Reducing Medications: Interactions with Harvoni® and Epclusa® Sofosbuvir/Velpatasvir = Epclusa® Ledipasvir/Sofosbuvir = Harvoni® • Acid-reducing medications can decrease the effectiveness of Harvoni® and Epclusa® and could prevent successful cure. • Let your provider know if you are taking any acid-reducing medications—either prescribed to you or purchased over the counter. Types of Acid-Reducing What to Do if What to Do if Medications Taking Epclusa® Taking Harvoni® Antacids Separate taking the antacid and Separate taking the antacid and Epclusa® by 4 hours Harvoni® by 4 hours Combinations of aluminum, magnesium, and calcium. Brand names include: Alka-Seltzer® Maalox® Mylanta® Rolaids® TUMS® H2 Blockers Do not take more than the Do not take more than the recommended doses recommended doses Cimetidine (Tagamet®) Famotidine (Pepcid®) May take together with Epclusa® May take together with Harvoni® Nizatidine (Axid®) or 12 hours apart or 12 hours apart Ranitidine (Zantac®) Proton Pump Inhibitors (PPI) It is best to avoid PPIs during treat- It is best to avoid PPIs during ment with Epclusa®. If there are no treatment with Harvoni®. If there Esomeprazole (Nexium®) alternatives, follow these instructions: are no alternatives, follow these Lansoprazole (Prevacid®) instructions: Omeprazole (Prilosec®) Take Epclusa® with food Pantoprazole (Protonix®) Take the proton pump inhibitor 4 Take Harvoni® and the proton Rabeprazole (Aciphex®) hours after taking Epclusa® pump inhibitor at the same time in the morning after fasting overnight Do not take the proton pump (on an empty stomach) inhibitor at the same time as Epclusa® Do not take proton pump Do not take proton pump inhibitors inhibitors at more than the at more than the recommended dose recommended dose U.S.
    [Show full text]
  • Effectiveness and Tolerability of Different Recommended Doses Of
    www.nature.com/scientificreports OPEN Effectiveness and Tolerability of Different Recommended Doses of PPIs and H2RAs in GERD: Network Received: 26 April 2016 Accepted: 15 December 2016 Meta-Analysis and GRADE system Published: 19 January 2017 Chao Zhang1, Joey S. W. Kwong2, Rui-Xia Yuan1,3, Hao Chen4, Chang Xu5, Yi-Pin Wang1, Gong-Li Yang6, Jin-Zhu Yan1, Le Peng1, Xian-Tao Zeng1, Hong Weng1, Jie Luo1 & Yu-Ming Niu1,6 Proton pump inhibitors (PPIs) and histamine-2-receptor antagonists (H2RAs) are used for gastro- esophageal reflux disease (GERD); however, the clinical evidence for treatment is poor. We evaluated the effectiveness and tolerability of different doses of PPIs,2 H RAs and placebo in adults with GERD. Six online databases were searched through September 1, 2016. All related articles were included and combined with a Bayesian network meta-analysis from randomized controlled trials (RCTs). The GRADE systems were employed to assess the main outcome. Ninety-eight RCTs were identified, which included 45,964 participants. Our analysis indicated that the full/standard dose of esomeprazole at 40 mg per day was the most efficient in healing among nine different dosages of PPIs and2 H RAs. The main efficacy outcome did not change after adjustments for the area, age, level of disease from endoscopy, year of publication, pharmaceutical industry sponsorship, Intention-to-treat (ITT)/per-protocol (PP), withdrawal rate, pre-set select design bias, single blinded and unblinded studies, study origination in China, study arms that included zero events, inconsistency node or discontinued drug were accounted for in the meta-regressions and sensitivity analyses.
    [Show full text]
  • Proton Pump Inhibitors in Veterinary Medicine
    American Journal of Animal and Veterinary Sciences Review Proton Pump Inhibitors in Veterinary Medicine 1Oguzhan Yavuz and 2Handan Hilal Arslan 1Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Ondokuz Mayis University, Samsun, Turkey 2Department of Internal Medicine, Faculty of Veterinary Medicine, Ondokuz Mayis University, Samsun, Turkey Article history Abstract: Inhibition of gastric acid secretion is necessary to treat many Received: 01-04-2017 gastrointestinal diseases. Proton Pump Inhibitors (PPIs) are very effective Revised: 02-06-2017 drugs, used for gastric acid inhibition and therapy of important erosive and Accepted: 23-06-2017 non-erosive gastrointestinal disorders in animals as well as humans. In this review, general properties of PPIs, their mode of action, pharmacokinetics, Corresponding Author: OguzhanYavuz efficacy, adverse effects, drug interactions and clinical and alternative uses Department of Pharmacology in veterinary medicine were evaluated. and Toxicology, Faculty of Veterinary Medicine, Keywords: Gastrointestinal Disorders, Proton Pump Inhibitors, Veterinary OndokuzMayis University, Medicine Samsun, Turkey Tel: 00903623121919/2830 Fax: 00903624576922 E-mail: [email protected] Introduction All clinically used PPIs contain a pyridyl methylsulfinyl benzimidazole group and differ only type Gastric acid is the secretion of parietal cells of of substituents on the pyridine and benzimidazole rings stomach and it is controlled by paracrine, endocrine and + + (Kosma et al ., 2016). Some important physicochemical neuronal systems. An important enzyme, H /K ATPase, properties of PPIs are shown in Table 1. is the main actor to pump hydrogen ions into the + + stomach lumen (H /K proton pump) (Shin and Sachs, Mode of Action 2008; Hori et al ., 2011; Garcia-Mazcorro et al ., 2012).
    [Show full text]
  • Pharmacodynamic Effects of Single Doses of Rabeprazole 20 Mg And
    Alimentary Pharmacology & Therapeutics Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn S.WARRINGTON*,K.BAISLEY*,D.LEE*,K.LOMAX ,B.DELEMOSà,M.BOYCE*&A.MOROCUTTI§ *Hammersmith Medicines Research SUMMARY Ltd, Central Middlesex Hospital, London, UK; Medical Affairs, Eisai Background Inc., Teaneck, NJ, USA; àPriCara, Unit Rabeprazole and pantoprazole are both used for symptomatic treatment of Ortho-McNeil Inc., Raritan, NJ, USA; §Medical Affairs, Eisai Ltd, of gastro-oesophageal reflux disease (GERD). Speed and duration of acid London, UK suppression and intensity of effect after a single dose may be important pharmacodynamic properties in clinical use. Correspondence to: Dr S. Warrington, Hammersmith Aim Medicines Research Ltd, Central Middlesex Hospital, Acton Lane, To compare antisecretory effects of single doses of rabeprazole and pan- London NW10 7NS, UK. toprazole in patients with GERD and a history of nocturnal heartburn. E-mail: [email protected] Methods An open-label, randomized, two-way crossover, clinical pharmacology Publication data Submitted 30 August 2006 study was conducted. Twenty-nine Helicobacter pylori-negative GERD First decision 5 September 2006 patients (17 men, mean age 44 years), with a history of nocturnal heart- Resubmitted 18 October 2006 burn (mean frequency 4.7 episodes/week), received a single dose of Accepted 6 November 2006 rabeprazole 20 mg or pantoprazole 40 mg, with a 14-day ‘washout’. In- tragastric pH was recorded continuously from 24 h before to 24 h after dosing. Results Mean area under the intragastric pH–time curve (AUC) was significantly higher after dosing with rabeprazole 20 mg than with pantoprazole 40 mg in all time intervals analysed, including night (P £ 0.02).
    [Show full text]
  • Early Effects of Oral Administration of Omeprazole and Roxatidine on Intragastric Ph
    Iida et al. / J Zhejiang Univ-Sci B (Biomed & Biotechnol) 2012 13(1):29-34 29 Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology) ISSN 1673-1581 (Print); ISSN 1862-1783 (Online) www.zju.edu.cn/jzus; www.springerlink.com E-mail: [email protected] Early effects of oral administration of omeprazole and roxatidine on intragastric pH Hiroshi IIDA1, Shingo KATO1, Yusuke SEKINO1, Eiji SAKAI1, Takashi UCHIYAMA1, Hiroki ENDO1, Kunihiro HOSONO1, Yasunari SAKAMOTO1, Koji FUJITA1, Masato YONEDA1, Tomoko KOIDE1, Hirokazu TAKAHASHI1, Chikako TOKORO1, Ayumu GOTO1, Yasunobu ABE1, Noritoshi KOBAYASHI1, Kensuke KUBOTA1, Eiji GOTOH2, Shin MAEDA1, Atsushi NAKAJIMA1, Masahiko INAMORI†‡1,3 (1Gastroenterology Division, Yokohama City University School of Medicine, Yokohama 236-0004, Japan) (2Department of Medical Education, Yokohama City University School of Medicine, Yokohama 236-0004, Japan) (3Office of Postgraduate Medical Education, Yokohama City University Hospital, Yokohama 236-0004, Japan) †E-mail: [email protected] Received Mar. 14, 2011; Revision accepted Aug. 30, 2011; Crosschecked Dec. 2, 2011 Abstract: Objective: The ideal medication for the treatment of acid-related diseases, e.g., peptic ulcers, stress- related gastric bleeding, functional dyspepsia, and gastroesophageal reflux disease, should have a rapid onset of action to promote hemostasis and relieve the symptoms. The aim of our study was to investigate the inhibitory effects on gastric acid secretion of a single oral administration of a proton pump inhibitor, omeprazole 20 mg, and an H2-receptor antagonist, roxatidine 75 mg. Methods: Ten Helicobacter pylori-negative male subjects participated in this randomized, two-way crossover study. Intragastric pH was monitored continuously for 6 h after single oral admini- stration of omeprazole 20 mg and roxatidine 75 mg.
    [Show full text]